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Editorial
Biomarkers in 
respiratory diseases
The December issue of Breathe focuses on 
biomarkers in respiratory diseases [1–4]. Biomarkers 
are measurable indicators of the presence, severity 
or type of a disease. They can help us understand 
the cause, phenotype, progression or regression, 
prognosis, or outcome of treatment of a disease. 
Biomarkers hold the promise of personalised 
 medicine, which aims to tailor treatments to 
 individual patients based on their biomarker profile 
and, by doing so, reduce the harms from ineffective 
treatments and increase the benefits from effective 
treatments. Biomarkers to describe disease 
 phenotypes and to determine optimal treatments 
based on these phenotypes are  receiving  substantial 
attention in the current respiratory research 
literature. The search for clinically useful biomarkers 
that impact clinical decision-making is, however, 
challenging, and the vast majority of biomarkers are 
failing at the initial verification and validation stages 
before they enter clinical practice [5].
As clinicians we are sometimes left to wonder, 
after reading a research article or listening to a 
talk of a prominent researcher, how we can apply 
the latest evidence on biomarkers into our clinical 
practice. This issue of Breathe aims to provide 
clinicians with a summary and update on some 
of these biomarkers. Unfortunately, while there 
are clinical applications for biomarkers, many 
uncertainties remain, as highlighted in a review 
article on the clinical utility of fractional exhaled 
nitric oxide in the management of asthma and 
COPD [1] and a review on basing COPD treatment 
choices, namely (inhaled) corticosteroid treatment, 
on blood eosinophil levels [2]. Antimicrobial 
stewardship considerations have driven research 
on biomarker guidance to identify patients who 
might not require treatment with antibiotics. 
Meta-analyses of randomised controlled trials 
suggest that procalcitonin-guided antibiotic 
therapy in lower respiratory tract infections 
and exacerbation of COPD can reduce the use 
of antibiotics without compromising clinical 
outcomes [6, 7]. Nevertheless, despite this 
evidence, a review article in this issue [3] found 
that major guidelines generally do not recommend 
that decisions about the need for antibiotic therapy 
in respiratory diseases are based on procalcitonin 
levels, indicating that some important uncertainties 
remain. The review authors conclude that 
procalcitonin levels provide supportive information 
that can inform the decision about antibiotic 
treatment in respiratory diseases in conjunction 
with a thorough clinical assessment [3].
The Patient Voice article provides a rare insight 
into how a patient experiences the role of biomarkers 
in the management of her asthma [4]. From reading 
this article, you will appreciate how important it is 
to communicate to patients if and how biomarkers 
impact on their recommended treatment.
As another year draws to a close, I would like 
to thank all contributors, editorial board members, 
the hard-working team at the European Respiratory 
Society publications office and our readers. Happy 
holidays!
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